HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation
详细信息 查看全文
- 作者：Martin McLaughlin ; Holly E. Barker ; Aadil A. Khan ; Malin Pedersen…
- 关键词：RAD51 ; FANCA ; ATM ; AUY922 ; HNSCC ; DDR
- 刊名：BMC Cancer
- 出版年：2017
- 出版时间：December 2017
- 年：2017
- 卷：17
- 期：1
- 全文大小：5180KB
- 刊物主题：Cancer Research; Oncology; Surgical Oncology; Health Promotion and Disease Prevention; Biomedicine, general; Medicine/Public Health, general;
- 出版者：BioMed Central
- ISSN：1471-2407
- 卷排序：17
文摘
BackgroundConcurrent cisplatin radiotherapy (CCRT) is a current standard-of-care for locally advanced head and neck squamous cell carcinoma (HNSCC). However, CCRT is frequently ineffective in patients with advanced disease. It has previously been shown that HSP90 inhibitors act as radiosensitizers, but these studies have not focused on CCRT in HNSCC. Here, we evaluated the HSP90 inhibitor, AUY922, combined with CCRT.